Spitalul Clinic Colentina

Running trials

• Recruiting

  A Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-Severe Plaque Psoriasis in Romania

  NCT07582783· Source

• Recruiting

  LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

  NCT07186101· Phase 2· Source

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Source

• Recruiting

  A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

  NCT07202884· Phase 3· Source

• Recruiting

  A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa

  NCT07136467· Source

• Recruiting

  Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  NCT06937086· Phase 3· Source

• Recruiting

  Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  NCT06937099· Phase 3· Source

• Recruiting

  A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

  NCT06056297· Phase 3· Source

• Active, not recruiting

  Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.

  NCT05930275· Source

• Active, not recruiting

  Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease

  NCT06107426· Source

• Recruiting

  Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency

  NCT05879757· Source

• Active, not recruiting

  Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease

  NCT05043103· Source

• Active, not recruiting

  Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

  NCT04562389· Phase 3· Source

• Active, not recruiting

  A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

  NCT04232553· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

  NCT03519945· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity3 recruiting
• Alopecia areata2 recruiting
• Hidradenitis suppurativa2 recruiting
• Ulcerative colitis2 recruiting
• Vitiligo2 recruiting
• Crohn's disease1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Multiple myeloma1 recruiting
• Psoriasis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

  NCT06153693· Phase 3· Source

• Completed

  Improvement of a Digital Health Platform for Remote Monitoring of Patients With Heart Failure

  NCT05708846· Source

• Completed

  A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

  NCT05651711· Phase 3· Source

• Completed

  A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review

  NCT05444972· Source

• Completed

  Endoscopy and Radiology-guided Ablation for Inoperable Cholangiocarcinoma

  NCT05563870· Source

• Terminated

  The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis

  NCT04985968· Phase 3· Source

• Completed

  Phase 3 Study to Evaluate the Safety and Efficacy of Hydrocortisone Acetate Suppositories

  NCT04469686· Phase 3· Source

• Completed

  Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis

  NCT03982394· Source

• Completed

  A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT03524092· Phase 3· Source

• Completed

  An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

  NCT03518086· Phase 3· Source

• Terminated

  Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

  NCT02629692· Phase 1/2· Source

• Completed

  A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease

  NCT02620046· Phase 3· Source

Trial sites

• Colentina Hospital1 trial
• Colentina Hospital Bucharest1 trial
• Gastroenterology Department, Colentina Hospital1 trial
• Spitalul Clinic Colentina18 trials
• Spitalul Clinic Colentina - Dermatology II0 trials
• Spitalul Clinic Colentina /ID# 2058600 trials
• Spitalul Clinic Colentina /ID# 2143071 trial
• Spitalul Clinic Colentina /ID# 2236800 trials
• Spitalul Clinic Colentina /ID# 2248101 trial
• Spitalul Clinic Colentina /ID# 2248111 trial
• Spitalul Clinic Colentina /ID# 2456201 trial
• Spitalul Clinic Colentina /ID# 2522501 trial
• Spitalul Clinic Colentina /ID# 2603551 trial
• Spitalul Clinic Colentina /ID# 2633030 trials
• Spitalul Clinic Colentina /ID# 2672080 trials
• Spitalul Clinic Colentina /ID# 2755061 trial
• Spitalul Clinic Colentina /ID# 2758171 trial
• Spitalul Clinic Colentina /ID# 2758920 trials
• Spitalul Clinic Colentina - parent0 trials
• Spitalul Clinic Colentina Site 11 trial
• Spitalul Clinic Colentina Site 21 trial
• Spitalul Clinic Colentina0 trials

Conditions

Diseases this institution publishes on or runs trials for.

• Systemic sclerosis (scleroderma)11 works · 0 trials